Short Interest in Sera Prognostics, Inc. (NASDAQ:SERA) Grows By 54.2%

15 Apr 2026, 16:18 by Amy Steele · The Cerbat Gem

Sera Prognostics, Inc. (NASDAQ:SERA – Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 381,493 shares, a growth of 54.2% from the March 15th total of 247,469 shares. Based on an average trading volume of 82,680 shares, the days-to-cover ratio is currently 4.6 days. Approximately 1.1% of the shares of the company are sold short.

Insider Activity at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 22,639 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total transaction of $43,014.10. Following the sale, the chief executive officer owned 741,287 shares of the company’s stock, valued at approximately $1,408,445.30. This trade represents a 2.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 55,133 shares of company stock valued at $109,794. 13.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cetera Investment Advisers acquired a new stake in shares of Sera Prognostics in the 4th quarter valued at $74,000. Barclays PLC lifted its holdings in Sera Prognostics by 267.4% during the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock valued at $108,000 after purchasing an additional 26,726 shares during the last quarter. Jane Street Group LLC acquired a new position in Sera Prognostics in the fourth quarter valued at about $203,000. Wealth Enhancement Advisory Services LLC acquired a new position in Sera Prognostics in the fourth quarter valued at about $31,000. Finally, Lido Advisors LLC bought a new stake in Sera Prognostics during the third quarter worth about $68,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Stock Up 1.9%

SERA traded up $0.04 during midday trading on Wednesday, reaching $2.18. 5,621 shares of the company’s stock were exchanged, compared to its average volume of 58,284. Sera Prognostics has a one year low of $1.37 and a one year high of $4.09. The firm has a market capitalization of $85.33 million, a price-to-earnings ratio of -3.21 and a beta of 1.05. The business has a 50-day simple moving average of $2.19 and a two-hundred day simple moving average of $2.87.

Sera Prognostics (NASDAQ:SERA – Get Free Report) last issued its earnings results on Wednesday, March 18th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.03 million. Sera Prognostics had a negative return on equity of 37.50% and a negative net margin of 39,417.29%. As a group, research analysts anticipate that Sera Prognostics will post -0.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Get Our Latest Research Report on Sera Prognostics

Sera Prognostics Company Profile

(Get Free Report)

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.